FDA Approves Personalized Tx for Metastatic Bladder Cancer

15:00 EDT 12 Apr 2019 | Drugs.com

FRIDAY, April 12, 2019 -- The first personalized treatment for patients with metastatic bladder cancer and susceptible fibroblast growth factor receptor (FGFR) genetic alterations was granted accelerated approval by the U.S. Food and Drug...

Original Article: FDA Approves Personalized Tx for Metastatic Bladder Cancer

More From BioPortfolio on "FDA Approves Personalized Tx for Metastatic Bladder Cancer"